알레르기 면역요법 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Allergy Immunotherapy Market

The future of the global allergy immunotherapy market looks promising with opportunities in the allergic rhinitis and allergic asthma markets. The global allergy immunotherapy market is expected to reach an estimated $7.6 billion by 2035 from $4.3 billion in 2027 with a CAGR of 7.1% from 2027 to 2035. The major drivers for this market are the increasing prevalence of allergic conditions, the rising awareness of allergy treatments, and the growing adoption of personalized therapies.

• Lucintel forecasts that, within the type category, subcutaneous immunotherapy is expected to witness higher growth over the forecast period due to evidence that shows that subcutaneous immunotherapy is effective in treating severe allergies.
• Within the application category, allergic rhinitis is expected to witness higher growth over the forecast period due to heightened exposure to environmental allergens.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to pollution is on the rise and so are the number of medical diagnoses for allergies.

Emerging Trends in Allergy Immunotherapy Market

Between 2025 and 2027, Allergy immunotherapy will shift toward early detection and home treatment. During this period, treatment will also focus on modifying the condition to slow its progression. Lucintel believes that changes in the allergy and immunotherapy market will increase the demand for allergy therapy. This will be a result of improvements in payer coverage, development of novel biologics and other products, and other trends.

• Personalized Treatment: Increasing focus on individual risk will influence the prescription of allergy treatment. Additional oral products from the FDA will also influence the expansion of oral immunotherapy. In 2025, guidelines also introduced a risk-benefit approach to the consideration of peanut and tree nut allergy treatment. Similar trends are anticipated in the pricing and market positioning of allergy treatment.
• Home Treatment: Recent advances have also enabled the modification of treatment for allergic conditions to be conducted at home. These include the use of connected devices to monitor treatment adherence and telehealth to conduct remote monitoring.
• Food Allergy Treatment: The recent approval of a product to modify food allergy has also created an avenue for the development of other products to modify allergy conditions. The recent focus of the biopharmaceutical industry on modifying food allergy conditions is expected to continue.
• Digital Patient Support: Symptom diaries, automated reminders, and remote coaching enable providers and manufacturers to support patients in managing symptoms, and adhering to and persisting on their treatment. Digital techniques will facilitate generation of real-world data on treatment adherence and will help address unintentional treatment discontinuation. Therefore, digital approaches will facilitate restoration of reimbursed treatment and will be useful at least until 2030.
• Sustainable Manufacturing: Pharmaceutical companies have reporting requirements that integrate health care sustainability. As a result, suppliers are modifying their facilities and supply chain to improve their resource efficiency. Manufacturing changes require considerable capital. Companies expect their suppliers will invest in improving resource efficiency. Changes in health care provider companies' procurement processes to incorporate sustainable manufacturing will accelerate.

Ultimately, success in the market will be determined by the ability to develop effective treatment options for food allergy that can be administered to patients outside the healthcare system. Other advantages such as treatment persistence will contribute to the market success. Integrating digital technologies will enhance treatment safety. Regulations that facilitate manufacturers' entry into the food allergy market will help ensure that patients have access to safe, and effective treatment options.

Recent Developments in the Allergy Immunotherapy Market

Between 2025 and 2027, we expect the allergy immunotherapy market to expand as sublingual tablets become more widely available, biologics-based allergic rhinitis products arrive, and market players assess the long-term economic impact of these products. According to Lucintel, the demand will be driven by the increasing prevalence of allergic rhinitis. However, there are obstacles such as the level of acceptance and willingness of the patient to adhere to the treatment, as well as the availability of specialized personnel.

• Regulatory Environment: The U.S. Food and Drug Administration (FDA) and the European agencies are facilitating the development of standardized sublingual immunotherapy products. The FDA's approval of Odactra for use by patients 5 through 65 years of old (June 2024) sets a regulatory precedent that will allow other sublingual tablet products to be marketed. A shift in product availability may allow primary care physicians to administer the products in a office or clinic setting.
• Manufacturing Environment: The supply of standardized allergen extracts is anticipated to increase. In 2025, Staller genes Greer announced a three-year, $100 million investment to increase the capacity of its manufacturing facilities. The increased supply may allow companies to expand the geographic markets in which they can sell their products.
• Strategic Partnerships: Allergy drug developers are partnering with companies that specialize in adherence and diagnosis to create end-to-end solutions. Allergy drugs, in particular, benefit from continuous patient monitoring to assess treatment persistence. The 2025 collaboration between the two aforementioned companies was worth around $20 million.
• New Avenues of Research: Some companies explore the combination of allergen immunotherapy with biologics. Positive results of these ongoing clinical trials are likely to broaden the scope of the patient population for which the treatment is indicated and increase average revenue per patient.
• Evidence of Sustained Benefit: In 2025, some Allergy drug companies providing products reimbursed by the European Union, had to show that patients continued to benefit from the product in the 2nd and 3rd year of treatment. Products supported by evidence of patient adherence and persistence over a 3-year period met the above requirement.

Allergy drug companies have to invest substantially to increase the addressable patient population by broadening the indication for which their drugs are reimbursed. However, success will depend on a company's ability to demonstrate that their product meets the requirement of durable disease modification. Failure to do so will result in price control and reimbursement restriction by health care benefit payers and specialists.

Strategic Growth Opportunities in the Allergy Immunotherapy Market

An increase in allergies from 2024-2026 is expected to drive demand for allergy treatments. During this timeframe, reducing the cost of medications is also expected to put increasing demand on the supply of allergy treatments. Digital consultations will allow treatments to be given in the home. According to Lucintel, the allergy immunotherapy market will see growth by 2026, primarily due to investment in the biologics market and improvements in access to care.

• Paediatric Populations: In June 2025 the FDA approved ODACTRA for use in patients 5-17 years of age. Newer and more effective interventions for treating allergies may gain coverage and reimbursement if they lead to improved outcomes for patients.
• Home Therapies: SLIT has the potential to be a highly profitable allergy treatment. In 2024, ALK reported that their allergy treatment sales reached 5.1 billion DKK. In the coming years, allergists will be able to treat more patients and help control their symptoms.
• Biologic Combination Therapies: In February 2025 the FDA approved biologics to treat asthma. There are a number of patients that do not benefit from the use of current allergy treatments. Combination therapies that include the use of biologics may treat patients that do not benefit from the use of allergy treatments.
• Making Allergy Treatment More Accessible: Local manufacturing and variance in pricing make allergy treatment more accessible in other regions. May 2025 was a landmark date as the population of India reached 1.4 billion. Each year provides additional opportunities for training more physicians and expanding the population that can be treated.
• Adherence Services: Telehealth services and electronic reminders can improve treatment adherence. The use of electronic devices to manage health increased in 2025. Electronic devices can also be used to improve treatment adherence. Improved adherence can also facilitate the reimbursement of treatment.

In the next five years, regional manufacturing and the adoption of allergy treatment in the pediatric population will increase. The treatment of allergies will become more integrated into various healthcare pathways. Biologic combinations will also increase. The focus on adherence will also continue. Manufacturing and distributing allergy treatment will remain more lucrative in developed countries.

Allergy Immunotherapy Market Drivers and Challenges

The immunotherapy market is expected to grow due to advancements in technology and changes in the economics, regulations and attitudes toward allergic diseases and health care. The focus on improving symptoms has now expanded to include other means of modifying allergic diseases. The availability of more convenient, tolerable and effective ways to treat allergic diseases has increased the demand for allergy immunotherapy. Patents covering allergy immunotherapy have expired, creating a more competitive marketplace. Restrictive reimbursement policies and the need for lengthy treatment regimens continue to limit the market potential. The outcome of future clinical trials will determine the market potential of allergy immunotherapy. The most promising opportunity for competitive advantage will be captured by those companies that are able to commercialize the innovative allergy immunotherapies in a timely manner.

The factors responsible for driving this market include:

• Rising Cases of Allergies: The number of people suffering from allergic conditions is increasing due to exposure to various environmental factors. According to the World Health Organization (WHO), hundreds of millions of people suffer from allergic conditions and related conditions. In 2025, Public Health England documented a significant increase in the awareness of allergic conditions. The longer duration of pollen shedding and exposure of various environmental conditions facilitate the diagnosis of allergic conditions. Consequently, there will be an increase in the demand for therapies to manage allergic conditions in the coming years. Additionally, the awareness of the public on available treatments for allergic conditions will increase, especially on the availability of immunotherapies to manage and prevent allergic conditions.
• Availability of New Technologies: In the coming years, the allergy immunotherapy market will be enhanced with the development of new technologies. The collaboration of biotechnology and other related disciplines will improve diagnosis of various allergic conditions and develop immunotherapies. Digital adherence technology will improve the confidence of healthcare providers in remote management of allergic conditions and other chronic conditions. Hospitals will be able to provide personalized management for allergic conditions based on the recommendations of remote healthcare providers.
• Regulatory and Clinical Support: Standardized allergen products are gaining regulatory and clinical acceptance. Immunotherapy products are available in major markets. Long-term immune responses and indication expansion are evaluated. Regulatory pathways allow for post-market research and increase product acceptability. Product credibility will increase if evidence of long-lasting benefits is generated. In the next 3-5 years, expected changes to the regulatory and reimbursement landscape, coupled with revised clinical practice guidelines, will allow for the integration of Allergy Immunotherapy for select patient populations.
• Demand for Long-Term Disease Modification: Allergic patients prefer long-term therapies to control their symptoms rather than relying on the use of rapidly acting emergency and/or symptom-modifying therapies. Allergy Immunotherapy is receiving increased attention. Many expect long-lasting and durable benefits from therapy. The use of Allergy Immunotherapy is increasing, and both the sublingual and injectable routes of administration are gaining preference. In the next 3-5 years, therapies offering long-term benefits and durability will be welcomed by the patient population, particularly if they decrease symptom frequency and severity and allow for improvement in quality of life.
• Manufacturing and Distribution: Allergen extraction and quality control processes have improved, as have cold-chain and specialty pharmacy logistics. Digital prescription and dispense technologies allow for the traceability of prescription medications. Manufacturers have adopted these processes in order to ensure consistent and reliable allergy treatment. Visibility to the allergy treatment supply chain has been the focus of several Federal initiatives. Continuity of treatment is directly correlated to supply chain interruptions. Further manufacturing improvements should facilitate an increase in the number of standardized allergy treatment options. Manufacturing enhancements and process improvements should lower the cost of these treatments and improve access. During the next 5 years, the focus of allergy treatment manufacturers should be to expand their product offerings and extend the geographic reach of their offerings beyond the allergist's office.

The challenges facing this market include:

• High Treatment Cost and Lack of Reimbursement: The cost of treatment over the long term places an enormous burden on the patient and the allergist. Allergy treatment requires multiple office visits over several years. Treatment plans are often not initiated due to lack of insurance coverage. Even when treatment plans are initiated, there may not be adequate coverage for the entire treatment plan. Several barriers exist to the timely, and completion, of treatment plans. It is expected that in the next 5 years treatment plans will not be initiated, or completed, due to high out of pocket costs, even if lower long term costs (i.e. less asthmatic episodes, less allergy flare-ups, fewer medication usage, improved quality of life, improved workplace attendance, etc.) are achieved.
• Safety Concerns and Adherence Challenges: The potential for severe reactions after each injection, the need for many clinic visits, and the inability to stop treatment even after symptoms improve, all contribute to a lack of adherence to treatment among patients. Various procedures to reduce risks and increase safety have added to the time and cost required for treatment. As seen with sublingual alternatives, there are ways to reduce some of the barriers associated with treatment; however, these methods still require daily use. Improved adherence will likely occur only with the use of more innovative and less complex methods, and through better risk management and educational strategies.
• Inadequate Diagnosis and Allergist Capacity: There are untreated patients with allergic conditions, and trained nurses and allergists are not equally located throughout a given area. Long wait times for testing and the inability of some clinics to provide treatment for a large number of patients lead to an inadequate allocation of resources and restriction of treatment to only a small number of patients. This is likely to continue in the next several years, particularly in less-developed nations. While several strategies have been developed to better diagnose and test patients, including the use of telemedicine, the ongoing need to comply with various laws and the protection of patient safety will likely slow the distribution of treatment to a greater degree.

The growing prevalence of allergies, as well as higher awareness of allergies amongst the population, is expected to benefit the allergy immunotherapy market. More effective technology will allow companies to develop and commercialize products that will positively influence the allergy immunotherapy market. There are several barriers to market growth, including product costs, safety concerns, and the lack of specialty care providers. Barriers will likely allow market leaders to develop products that improve consumer compliance and increase the range of products distributed. Maintaining a balance between developing and commercializing products that meet consumer needs and embrace improving technology will allow companies to maintain market leadership. The focus of companies will likely be on innovating products while keeping the needs of consumers at the centre.

List of Allergy Immunotherapy Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies allergy immunotherapy market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the allergy immunotherapy market companies profiled in this report include-

• ALK-Abello
• Stallergenes Greer
• Merck
• Allergy Therapeutics
• HAL
• HollisterStier
• LETI

Allergy Immunotherapy Market by Segment

The study includes a forecast for the global allergy immunotherapy market by type, application, and region.

Allergy Immunotherapy Market by Type [Value ($B) from 2019 to 2035]:

• Subcutaneous Immunotherapy
• Sublingual Immunotherapy

Allergy Immunotherapy Market by Application [Value ($B) from 2019 to 2035]:

• Allergic Rhinitis
• Allergic Asthma
• Others

Allergy Immunotherapy Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Allergy Immunotherapy Market

The allergy immunotherapy market is growing because of more allowing manufacturers to produce sublingual tablets in more locations and because of a greater acceptance of sublingual therapies. About 2025-2027, companies plan to increase the number of products they can make and increase the labels on their products. The effects of these plans are causing increased market competition, both in established markets and in new markets, according to Lucintel.

• United States: Sublingual tablets, including Ondatra, Rag Witek, and Greste, have received FDA approval and are allowing patients to take allergy medication at home. In April 2025, Ondatra's label was expanded to allow children ages 5 to 11 to use the medication. It is expected that over the next several years, sublingual tablets, that can be taken at home, will be the dominant method of allergy immunotherapy for children.
• China: From 2024 to 2027, the Chinese National Medical Products Administration (NMPA) will be implementing a plan to allow for the domestic manufacture of innovative drugs. During the same time period, several companies in China developed methods to manufacture various allergens. It is expected that, during this time period, domestic manufacturing of allergens will increase and less allergens will need to be imported.
• Germany: The Paul-Ehrlich Institute is a leading European regulator of allergen products. The pharmaceutical industry in Europe, including Germany, invests in GMP-compliant facilities. The European Medicines Agency is expected to recommend 114 human medicines for approval in 2025. Therefore, Germany will remain an important manufacturing and regulatory base for the allergen products. European Union's pharmaceutical regulations and standards enhance the manufacturing capabilities, and facilitate the supply of medical products across the EU.
• India: The Indian government sponsored the National Biopharma Mission to promote the local manufacture of pharmaceuticals and biopharmaceuticals. Achieving self-reliance in the manufacture of biopharmaceuticals should enhance the local production of allergen extracts. This would be expected to create opportunities for joint ventures between Indian and international pharmaceutical companies.
• Japan: Torii and ALK are two companies that develop and commercialize sublingual allergy tablets. The Ministry of Health, Labour and Welfare of Japan approved Miti cure in 2018 for children aged 5 to 11 years.

Features of the Global Allergy Immunotherapy Market

• Market Size Estimates: allergy immunotherapy market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: allergy immunotherapy market size by type, application, and region in terms of value ($B).
• Regional Analysis: allergy immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the allergy immunotherapy market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the allergy immunotherapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the allergy immunotherapy market by type (subcutaneous immunotherapy and sublingual immunotherapy), application (allergic rhinitis, allergic asthma, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Allergy Immunotherapy Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Subcutaneous Immunotherapy : Trends and Forecast 2019 to 2035
• 4.4 Sublingual Immunotherapy : Trends and Forecast 2019 to 2035

5. Global Allergy Immunotherapy Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Allergic Rhinitis : Trends and Forecast 2019 to 2035
• 5.4 Allergic Asthma : Trends and Forecast 2019 to 2035
• 5.5 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Allergy Immunotherapy Market by Region

7. North American Allergy Immunotherapy Market

• 7.1 Overview
• 7.2 North American Allergy Immunotherapy Market by Type
• 7.3 North American Allergy Immunotherapy Market by Application
• 7.4 The United States Allergy Immunotherapy Market
• 7.5 Canadian Allergy Immunotherapy Market
• 7.6 Mexican Allergy Immunotherapy Market

8. European Allergy Immunotherapy Market

• 8.1 Overview
• 8.2 European Allergy Immunotherapy Market by Type
• 8.3 European Allergy Immunotherapy Market by Application
• 8.4 German Allergy Immunotherapy Market
• 8.5 French Allergy Immunotherapy Market
• 8.6 Italian Allergy Immunotherapy Market
• 8.7 Spanish Allergy Immunotherapy Market
• 8.8 The United Kingdom Allergy Immunotherapy Market

9. APAC Allergy Immunotherapy Market

• 9.1 Overview
• 9.2 APAC Allergy Immunotherapy Market by Type
• 9.3 APAC Allergy Immunotherapy Market by Application
• 9.4 Chinese Allergy Immunotherapy Market
• 9.5 Indian Allergy Immunotherapy Market
• 9.6 Japanese Allergy Immunotherapy Market
• 9.7 South Korean Allergy Immunotherapy Market
• 9.8 Indonesian Allergy Immunotherapy Market

10. ROW Allergy Immunotherapy Market

• 10.1 Overview
• 10.2 ROW Allergy Immunotherapy Market by Type
• 10.3 ROW Allergy Immunotherapy Market by Application
• 10.4 Middle Eastern Allergy Immunotherapy Market
• 10.5 South American Allergy Immunotherapy Market
• 10.6 African Allergy Immunotherapy Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Allergy Immunotherapy Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 ALK-Abello
  • Company Overview
  • Allergy Immunotherapy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Stallergenes Greer
  • Company Overview
  • Allergy Immunotherapy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Merck
  • Company Overview
  • Allergy Immunotherapy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Allergy Therapeutics
  • Company Overview
  • Allergy Immunotherapy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 HAL
  • Company Overview
  • Allergy Immunotherapy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Holister Stier
  • Company Overview
  • Allergy Immunotherapy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Leti
  • Company Overview
  • Allergy Immunotherapy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us